ES2170366T3 - Secuencia de adn aislada del gen brca1 y su utilizacion en terapia antitumoral. - Google Patents

Secuencia de adn aislada del gen brca1 y su utilizacion en terapia antitumoral.

Info

Publication number
ES2170366T3
ES2170366T3 ES97907894T ES97907894T ES2170366T3 ES 2170366 T3 ES2170366 T3 ES 2170366T3 ES 97907894 T ES97907894 T ES 97907894T ES 97907894 T ES97907894 T ES 97907894T ES 2170366 T3 ES2170366 T3 ES 2170366T3
Authority
ES
Spain
Prior art keywords
brca1
gene
dna sequence
isolated dna
brca1 gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97907894T
Other languages
English (en)
Inventor
Patricia D Murphy
Antonette C Allen
Christopher P Alvares
Brenda S Critz
Sheri J Olson
Denise B Schelter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENE LOGIC ACQUISITION CORP
Original Assignee
GENE LOGIC ACQUISITION CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24396174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2170366(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GENE LOGIC ACQUISITION CORP filed Critical GENE LOGIC ACQUISITION CORP
Application granted granted Critical
Publication of ES2170366T3 publication Critical patent/ES2170366T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SE REFIERE A SECUENCIAS CODIFICANTES AISLADAS Y A LAS SECUENCIAS DE PROTEINAS PARA LAS QUE CODIFICAN. ESTA INVENCION SE DIRIGE A TRES SECUENCIAS CODIFICANTES DEL GEN BRCA1. LAS TRES SECUENCIAS CODIFICANTES, BRCA1 SUP,OMI1}, BRCA1 SUP,OMI2}, BRCA1 SUP,OMI3} Y SUS FRECUENCIAS DE APARICION SE PROPORCIONAN JUNTO CON LAS SECUENCIAS DE PROTEINA PARA LAS QUE CODIFICAN. OTRO ASPECTO DE ESTA INVENCION ES UN METODO PARA DETERMINAR LA SECUENCIA CONSENSO PARA CUALQUIER GEN. OTRO ASPECTO DE ESTA INVENCION CONSISTE EN UN METODO PARA IDENTIFICAR UN INDIVIDUO QUE POSEA UNA SUSCEPTIBILIDAD GENETICA AUMENTADA A PADECER CANCER DE MAMA U OVARIO DEBIDO A QUE HAYA HEREDADO UNA MUTACION CAUSAL EN SU GEN BRCA1. ESTA INVENCION SE REFIERE TAMBIEN A UN METODO DE REALIZAR TERAPIA GENICA CON CUALQUIERA DE LAS SECUENCIAS CODIFICANTES BRCA1 AISLADAS.
ES97907894T 1996-02-12 1997-02-12 Secuencia de adn aislada del gen brca1 y su utilizacion en terapia antitumoral. Expired - Lifetime ES2170366T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/598,591 US5654155A (en) 1996-02-12 1996-02-12 Consensus sequence of the human BRCA1 gene

Publications (1)

Publication Number Publication Date
ES2170366T3 true ES2170366T3 (es) 2002-08-01

Family

ID=24396174

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97907894T Expired - Lifetime ES2170366T3 (es) 1996-02-12 1997-02-12 Secuencia de adn aislada del gen brca1 y su utilizacion en terapia antitumoral.

Country Status (14)

Country Link
US (2) US5654155A (es)
EP (3) EP0820526B1 (es)
JP (2) JPH11503924A (es)
AT (1) ATE208425T1 (es)
AU (1) AU1977897A (es)
BR (1) BR9702080A (es)
CA (1) CA2218251C (es)
DE (1) DE69707985T2 (es)
DK (1) DK0820526T3 (es)
ES (1) ES2170366T3 (es)
IL (1) IL121926A (es)
IS (1) IS4587A (es)
PT (1) PT820526E (es)
WO (1) WO1997029213A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403303B1 (en) * 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US6130322A (en) * 1996-02-12 2000-10-10 Gene Logic, Inc. Coding sequences of the human BRCA1 gene
US6951721B2 (en) * 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
US5912127A (en) * 1996-02-29 1999-06-15 Mcgill University Method and kit for evaluating risk of ovarian cancer in carriers of a BRCA1 mutation
WO1998001460A1 (en) * 1996-07-08 1998-01-15 Board Of Regents, The University Of Texas System Brca1 compositions and methods for the diagnosis and treatment of breast cancer
WO1998012327A2 (en) * 1996-09-20 1998-03-26 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
AU5093898A (en) * 1996-10-31 1998-05-22 Jennifer Lescallett Primers for amplification of brca1
US6048689A (en) * 1997-03-28 2000-04-11 Gene Logic, Inc. Method for identifying variations in polynucleotide sequences
EP0878552A1 (en) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
AU8776898A (en) * 1997-08-04 1999-02-22 Oncormed, Inc. Determining common functional alleles in a population and uses therefor
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
WO1999015704A1 (en) * 1997-09-23 1999-04-01 Oncormed, Inc. Genetic panel assay for susceptibility mutations in breast and ovarian cancer
US6030832A (en) * 1997-11-21 2000-02-29 Myriad Genetics, Inc. Carboxy-terminal BRCA1 interacting protein
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6897018B1 (en) 1998-02-25 2005-05-24 The United States Of America As Represented By The Department Of Health And Human Services DLC-1 gene deleted in cancers
JP2002513587A (ja) * 1998-05-04 2002-05-14 ダコ エー エス 染色体異常を検出するための方法およびプローブ
US6686163B2 (en) * 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
AU2003243357A1 (en) * 2002-06-06 2003-12-22 Johns Hopkins University School Of Medicine Allelic variation in human gene expression
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
TWI304321B (en) 2002-12-27 2008-12-11 Toray Industries Layered products, electromagnetic wave shielding molded articles and method for production thereof
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
AU2003301503A1 (en) * 2003-12-16 2005-07-14 Centre National De La Recherche Scientifique Methods and compositions for assaying mutations in nucleic acids
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
EP3075867B1 (en) * 2008-09-03 2019-03-13 Quantumdx Group Limited Sensing strategies and methods for nucleic acid detection using biosensors
US8372580B2 (en) 2008-11-21 2013-02-12 Morehouse School Of Medicine BRCA1 function-based cellular assays
WO2013064895A1 (en) 2011-10-31 2013-05-10 Genomic Vision Methods for the detection, visualization and high resolution physical mapping of genomic rearrangements in breast and ovarian cancer genes and loci brca1 and brca2 using genomic morse code in conjunction with molecular combing
EP2971111B1 (en) 2013-03-15 2018-05-02 Genomic Vision Methods for the detection of breakpoints in rearranged genomic sequences
WO2014140788A1 (en) 2013-03-15 2014-09-18 Genomic Vision Methods for the detection of sequence amplification in the brca1 locus
EP3839974B9 (en) 2019-12-20 2023-05-03 Dynamic Code AB Method for analysing the likelihood of diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5593840A (en) 1993-01-27 1997-01-14 Oncor, Inc. Amplification of nucleic acid sequences
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
ATE201445T1 (de) * 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
ATE198623T1 (de) * 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene

Also Published As

Publication number Publication date
JPH11503924A (ja) 1999-04-06
WO1997029213A1 (en) 1997-08-14
DE69707985T2 (de) 2002-10-31
CA2218251C (en) 2010-10-19
AU1977897A (en) 1997-08-28
US5654155A (en) 1997-08-05
EP1126034A2 (en) 2001-08-22
EP1126034A3 (en) 2001-08-29
EP0820526A1 (en) 1998-01-28
EP2351854A1 (en) 2011-08-03
DE69707985D1 (de) 2001-12-13
EP0820526A4 (en) 1998-07-08
IL121926A (en) 2006-08-01
BR9702080A (pt) 1999-12-28
US5750400A (en) 1998-05-12
IL121926A0 (en) 1998-03-10
CA2218251A1 (en) 1997-08-14
DK0820526T3 (da) 2002-03-04
EP0820526B1 (en) 2001-11-07
IS4587A (is) 1997-10-10
ATE208425T1 (de) 2001-11-15
JP2012090627A (ja) 2012-05-17
PT820526E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
ES2170366T3 (es) Secuencia de adn aislada del gen brca1 y su utilizacion en terapia antitumoral.
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
ATE314482T1 (de) Rekombinante adenoviren-vektor und verfahren zur verwendung
DK0858467T3 (da) Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
FI881185A0 (fi) Human mangan-superoxiddismutas (hmn-sod).
ATE315087T1 (de) Neuartige auf p53 ansprechende gene
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
DE69637156D1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
ATE309536T1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
ATE362536T1 (de) Gdp-dissoziation stimulierendes protein, gehirnspezifisches nucleosomfügungsprotein, skelettmuskel-spezifisches ubiquitin- conjugationsenzym, zellproliferationsprotein, phosphatidylinositolkinase, nel verwandte proteine
DE69731834D1 (de) Agouti verwandtes gen
ATE380195T1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
DE69524740D1 (de) Thymidin-kinase-mutanten
FI863188A0 (fi) Kombinationsfoerfaranden foer producering av serinproteas-inhibitorer och foer dessa anvaendbara dna-sekvenser.
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
DE69117123D1 (de) Menschliches MK Gen und Protein-Sequenz
DE69941273D1 (de) Zusammenstellung und Verfahren zur Diagnose von Tumoren
ATE517122T1 (de) Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
DE69110034D1 (de) Methoden und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen.
DE69931759D1 (de) Methode zur erstellung von genexpressionsprofilen
DE59712554D1 (de) Rekombinante expression von s-layer-proteinen
DE69733491D1 (de) In Krebszellen überexprimiertes Genprodukt
ATE207536T1 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6
MX9707259A (es) Homologos de celubrevinas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 820526

Country of ref document: ES